Delivery Order SPE2DB24D1205-SPE2DB25FCZHB
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 30 mg capsules (100 count) under a firm fixed-price contract with a ceiling value of $2,136.69. The award, effective September 2, 2025, with an ultimate completion date of September 3, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,977.61 to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 30 mg capsules (100 count) on August 22, 2025, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price delivery order was issued under a child contract arrangement with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 40 mg capsules (100-count) valued at $2,057.66. The contract, which closed on August 28, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will be fulfilled from the contractor's Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate office. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,140.26 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Lisdexamfetamine 30 mg capsules in quantities of 100 units. The contract carries a firm fixed price structure with no set-aside designation and is scheduled for ultimate completion by August 18, 2025. Performance will be executed from the contractor's facility located in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 50 mg capsules (100 count) with a ceiling value of $6,451.66. The contract was awarded on August 20, 2025, with an ultimate completion date of August 21, 2025, under a firm fixed-price delivery order arrangement. No set-aside designation was utilized in this competitive procurement. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,401.40 to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Lisdexamfetamine 30 mg capsules (100 count). This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of July 29, 2025. The contract is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 50 mg capsules (90-unit package) valued at $2,510.96. This competitively awarded, firm fixed-price delivery order was issued on September 4, 2025, with an ultimate completion date of September 5, 2025. The contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $1,706.90 firm fixed price delivery order to AmerisourceBergen Drug Corp for Lisdexamfetamine 10 mg capsules (100 count) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-set-aside contract was performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen Drug Corp's broader pharmaceutical supply relationship with the DLA. This award is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,530.00 to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 70 mg capsules (90-count packaging) under a firm fixed-price contract type. The award was made on August 14, 2025, with an ultimate completion date of August 15, 2025, and no set-aside designation was utilized in this competitive procurement. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 60 mg capsules (100-count units) under a firm fixed price contract valued at $3,094.80, with an ultimate completion date of August 26, 2025. This non-set-aside competitive award was issued on August 25, 2025, with performance to occur at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a continuation of AmerisourceBergen's ongoing...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZHBDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 30 mg capsules in a quantity of 90 units under a firm fixed-price contract type. The award, made on August 7, 2025, carries a ceiling value of $2,062.24 with an ultimate completion date of August 8, 2025. This is a non-set-aside competitive award, and the pharmaceutical product will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.9 billion global pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal vendor supplying medications and medical supplies to support military healthcare programs and other government healthcare systems. The company's federal contract portfolio demonstrates extensive experience fulfilling diverse pharmaceutical requirements across multiple therapeutic domains through competitively awarded delivery orders with firm fixed pricing structures.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 8/7/25 |